{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:26:41Z","timestamp":1649212001619},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ijcard.2014.03.202","type":"journal-article","created":{"date-parts":[[2014,4,6]],"date-time":"2014-04-06T11:50:06Z","timestamp":1396785006000},"page":"e4-e6","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Myasthenia gravis and heart failure: Is ivabradine a useful drug?"],"prefix":"10.1016","volume":"174","author":[{"given":"Elio","family":"Venturini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pellegrinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Marabotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Magni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.03.202_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00005792-197809000-00002","article-title":"Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy","volume":"57","author":"Namba","year":"1978","journal-title":"Medicine"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00131402-200306000-00006","article-title":"Cardiac disease in myasthenia gravis: a literature review","volume":"4","author":"Guglin","year":"2003","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"505","key":"10.1016\/j.ijcard.2014.03.202_bb0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"1987","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0025","first-page":"301","article-title":"Electrocardiographic findings in 24 patients with myasthenia gravis","volume":"31","author":"Buyukozturk","year":"1976","journal-title":"Acta Cardiol (Brux)"},{"issue":"3","key":"10.1016\/j.ijcard.2014.03.202_bb0030","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","article-title":"Heart disease in myasthenia gravis","volume":"70","author":"Hofstad","year":"1984","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"10.1016\/j.ijcard.2014.03.202_bb0035","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archneurol.2009.231","article-title":"Herzmyasthenie: myasthenia of the heart","volume":"66","author":"Aarli","year":"2009","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.ijcard.2014.03.202_bb0040","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000117380","article-title":"Fulminant myasthenia gravis soon after initiation of acebutolol therapy","volume":"30","author":"Confavreux","year":"1990","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0050","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7326\/0003-4819-83-6-834","article-title":"Beta blockers and myasthenia gravis","volume":"83","author":"Herishanu","year":"1975","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ijcard.2014.03.202_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/157489009787260016","article-title":"Ivabradine: cardiovascular effects","volume":"4","author":"Rognoni","year":"2009","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"10.1016\/j.ijcard.2014.03.202_bb0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2014.03.202_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314006524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314006524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T03:54:28Z","timestamp":1538711668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314006524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0167527314006524"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.03.202","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis and heart failure: Is ivabradine a useful drug?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.03.202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}